A decision on the medicine trade should be judged by what happens at the covered remedy row in the Lower Market Hall. The docket is at step 2 of the current review. Its latest entry reads: The clerk has matched the claim to its source register and named the missing record. A rule that looks complete in the chamber can still leave the people who use it carrying an unmeasured cost.
17 bundles carrying a verified origin mark were entered this cycle, compared with 14 in the prior file. That comparison matters because the public summary counts entries. The open question is whether the origin check protects buyers without pricing local gatherers out of the hall.
The steward says a traceable mark prevents substitution; gatherers say the new inspection fee exceeds the value of a small bundle. The current record does not settle that disagreement. The objection deserves a direct answer, but it is not a reason to make the rule permanent before the affected residents can check the method.
Nima Thol checked the remedy row’s origin tags and the public price board against the field notes. The method is to put the posted price beside the amount that actually changed hands; it confirms the entries, but not every interpretation attached to them. The practical evidence is the blue thread tied around each bundle inspected by the remedy steward; any new measure should record that condition beside the total.
The chamber should approve a limited trial with a published end date, a way to record exceptions and a named reviewer. The hall will review the fee beside the last three market prices. That is the narrowest decision that can be defended from the evidence now available.
